Kronos Bio Announces Participation in the Cowen 41st Annual Health Care ConferenceGlobeNewsWire • 02/22/21
Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified CancersGlobeNewsWire • 12/07/20
Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial ResultsGlobeNewsWire • 11/18/20
Kronos Bio Announces Participation in the Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/11/20
Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 10/14/20